Do you want to read an article? Please log in or register.
Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma
Lung, Respiratory and Thoracic CancerLymphoma
Related content
Lung, Respiratory and Thoracic CancerLymphoma
Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib
Lung Cancer.
Zhu VW, Cui JJ, Fernandez-Rocha M, Schrock AB, Ali SM, Ou SI
doi: 10.1016/
Lung, Respiratory and Thoracic Cancer
Anaplastic lymphoma kinase (ALK) Gene Rearrangement in Children and Young Adults with Mesothelioma
J Thorac Oncol.
Mian I, Abdullaev Z, Morrow B, Kaplan RN, Gao S, Mettienen M, Schrump DS, Zgonc V, Wei JS, Khan J, Pack S, Hassan R
doi: 10.1016/j.jtho.2019.11.011.
Lung, Respiratory and Thoracic CancerLymphoma
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial
Lancet Oncol.
Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Tugnait M, Narasimhan NI, Dorer DJ, Kerstein D, Rivera VM, Clackson T, Haluska FG, Camidge DR
doi: 10.1016/
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Lurbinectedin in Refractory Diffuse Malignant Peritoneal Mesothelioma: Report of Two Cases
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Front Oncol
Gros L, Szturz P, Diciolla A, Kirchner V, Peters S, Schaefer N, Hubner M, Digklia A
doi: 10.3389/fonc.2021.704295
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Lurbinectedin in Refractory Diffuse Malignant Peritoneal Mesothelioma: Report of Two Cases
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Front Oncol
Gros L, Szturz P, Diciolla A, Kirchner V, Peters S, Schaefer N, Hubner M, Digklia A
doi: 10.3389/fonc.2021.704295
Lung, Respiratory and Thoracic CancerMultiple Myeloma (MM)
Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group
Arch Pathol Lab Med.
Husain AN, Colby TV, Ordóñez NG, Allen TC, Attanoos RL, Beasley MB, Butnor KJ, Chirieac LR, Churg AM, Dacic S, Galateau-Sallé F, Gibbs A, Gown AM, Krausz T, Litzky LA, Marchevsky A, Nicholson AG, Roggli VL, Sharma AK, Travis WD, Walts AE, Wick MR
doi: 10.5858/arpa.2017-0124-RA.
WCLC 2020
Lung, Respiratory and Thoracic Cancer
Malignant Mesothelioma
Fennel D et al. 2021. Nivolumab Versus Placebo in Relapsed Malignant Mesothelioma: The CONFIRM Phase 3 Trial. Oral presentation presented at: WCLC 2020; 28−31 January 2021.
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Efficacy, Safety and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Cancer Discov
Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, Parra Cuentas ER, Chen H, Villalobos P, Verma A, Mahvash A, Hwu P, Cortazar P, McKenna E, Yun C, Dervin S, Schulze K, Darbonne WC, Morani AC, Kopetz S, Fournier KF, Woodman SE, Yao JC, Varadhachary GR, Halperin DM
doi: 10.1158/2159-8290.CD-21-0331
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Efficacy, Safety and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Cancer Discov
Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, Parra Cuentas ER, Chen H, Villalobos P, Verma A, Mahvash A, Hwu P, Cortazar P, McKenna E, Yun C, Dervin S, Schulze K, Darbonne WC, Morani AC, Kopetz S, Fournier KF, Woodman SE, Yao JC, Varadhachary GR, Halperin DM
doi: 10.1158/2159-8290.CD-21-0331